Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma
Recently, a number of targeted agents have demonstrated single-agent activity in the
treatment of advanced renal cell carcinoma. Bevacizumab, a humanized monoclonal antibody
directed against VEGF, resulted in an improvement in median progression-free survival when
compared to placebo in a prospective, randomized trial. More recently, the multitargeted
agents sorafenib and sunitinib have been approved for use in the treatment of advanced renal
cell carcinoma. Both have proven superior to previous interferon and other standard
treatment; however it is not clear how these drugs should be used in the treatment sequence.
With roughly 80% of cancer patients receiving their oncology care in the community setting,
we are proposing a review and evaluation of at least 200 advanced renal cell carcinoma
Observational Model: Case-Only, Time Perspective: Retrospective
To evaluate the safety and efficacy of Nexavar as second-line therapy in patients with advanced renal cell carcinoma treated with Nexavar after first-line therapy with Sutent or Avastin.
Jeffrey F Patton, M.D.
Sarah Cannon Research Institute
United States: Institutional Review Board
SCRI OUTCOMES 06
|Northeast Arkansas Clinic||Jonesboro, Arkansas 72401-3125|
|Consultants in Blood Disorders and Cancer||Louisville, Kentucky 40207|
|Medical Oncology Associates of Augusta||Augusta, Georgia 30901|
|Gulfcoast Oncology Associates||St. Petersburg, Florida 33705|
|St. Louis Cancer Care||Chesterfield, Missouri 63017|
|Tennessee Oncology, PLLC||Clarksville, Tennessee 37043|
|Jackson Oncology Associates||Jackson, Mississippi 39202|
|Oncology Hematology Care||Cincinnati, Ohio 45242|